Eczema – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 17 Jun 2026 04:02:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Eczema – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-study-of-lebrikizumab-with-placebo-in-children-6-months-to-18-years-with-moderate-to-severe-atopic-dermatitis/ Wed, 13 May 2026 05:05:02 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-study-of-lebrikizumab-with-placebo-in-children-6-months-to-18-years-with-moderate-to-severe-atopic-dermatitis/ This clinical trial is being done in children and teenagers ages 6 months to under 18 years who have Atopic Dermatitis, also called eczema, that is moderate to severe. The study uses lebrikizumab, a medicine given as an injection under the skin, and a placebo to match LY3650150. The purpose of the study is to learn more about the long-term safety of lebrikizumab in this age group.

Participants receive study treatment over a long period of time and are followed during the study to see how they do. Some participants may receive lebrikizumab, while others may receive the placebo to match LY3650150. The study is designed to gather information over time about how safe the treatment is and how well it works for this skin condition.

]]> Study on the Safety and Effectiveness of Metal Panel Allergens for Diagnosing Allergic Contact Dermatitis and Eczema in Patients https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-metal-panel-allergens-for-diagnosing-allergic-contact-dermatitis-and-eczema-in-patients/ Wed, 29 Apr 2026 15:05:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-metal-panel-allergens-for-diagnosing-allergic-contact-dermatitis-and-eczema-in-patients/ This clinical trial is focused on studying the safety and effectiveness of a group of substances known as Metal Panel Allergens. These substances are used to test for allergic contact dermatitis, a type of skin reaction that occurs when the skin comes into contact with certain metals. The study will use a special patch test to apply these allergens to the skin. The allergens being tested include Nickel Sulfate, Copper Sulfate, Tin Chloride, Manganese Chloride, Zinc Chloride, Cobalt Chloride, Gold Sodium Thiosulfate, Sodium Tetrachloropalladate, Vanadium Oxide Sulfate, Ammonium Titanium Oxalate, and Potassium Dichromate. These substances are applied to the skin using a device called the allergEAZE Patch Test Chamber, which helps to deliver the allergens in a controlled manner.

The purpose of the study is to evaluate how well these allergens can diagnose allergic contact dermatitis and to ensure they are safe to use. Participants will have the allergens applied to their skin in the form of patches, which will remain in place for a short period. The study will monitor any skin reactions that occur, which can help determine if a person is allergic to any of the metals tested. The study will also compare the results of this patch test method with a reference method to see how well they agree.

The trial will take place over a period of time, with participants being monitored for any reactions to the allergens. The study aims to provide valuable information on the safety and performance of these metal allergens in diagnosing allergic contact dermatitis. This information could help improve the way allergies to metals are diagnosed and managed in the future.

]]> Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children https://clinicaltrials.eu/trial/study-on-the-effect-of-a-new-moisturiser-with-paraffin-and-liquid-paraffin-on-preventing-eczema-relapse-in-children/ Wed, 29 Apr 2026 14:25:02 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-a-new-moisturiser-with-paraffin-and-liquid-paraffin-on-preventing-eczema-relapse-in-children/ This clinical trial is focused on studying the effects of a new moisturizer on preventing the relapse of atopic dermatitis, commonly known as eczema, in children. The study will compare the new moisturizer with a reference cream to see which is more effective in keeping eczema from coming back. The trial involves several creams, including Essex, creme which contains paraffin, Advantan® 0.1% Creme with methylprednisolone aceponate, Linola Fett with unsaturated fatty acids, ECURAL® Fettcreme containing mometasone furoate, and Miniderm Duo with glycerol and urea.

The purpose of the study is to demonstrate the superiority of the newly developed moisturizer in preventing eczema relapse in children. Participants will apply the creams topically, meaning directly on the skin, over a period of time. The study will monitor how long it takes for eczema to return and how many participants remain eczema-free over several months. The creams will be provided in identical containers to ensure the study remains unbiased.

Throughout the study, various aspects will be assessed, such as the severity of the disease, the intensity of itching, and the quality of life of the participants. The study will also look at how much cream is used and gather feedback on the creams’ properties. Additionally, the study will monitor any adverse effects that may occur during the trial period. The goal is to find an effective way to manage and prevent eczema in children, improving their overall well-being.

]]> Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis https://clinicaltrials.eu/trial/study-of-lebrikizumab-and-topical-corticosteroids-for-children-and-teens-with-moderate-to-severe-atopic-dermatitis/ Wed, 29 Apr 2026 14:23:59 +0000 https://clinicaltrials.eu/trial/study-of-lebrikizumab-and-topical-corticosteroids-for-children-and-teens-with-moderate-to-severe-atopic-dermatitis/ This clinical trial is focused on studying the effects of a medication called Lebrikizumab on children and adolescents aged 6 months to under 18 years who have moderate-to-severe atopic dermatitis, commonly known as eczema. Eczema is a condition that makes the skin red, inflamed, and itchy. The study aims to evaluate how effective and safe Lebrikizumab is when used alongside topical corticosteroids, which are creams or ointments applied to the skin to reduce inflammation and irritation.

Participants in the study will receive either Lebrikizumab or a placebo, which is a substance with no active medication, to compare the outcomes. The treatment will be administered as a solution for injection under the skin. The study will monitor the participants over a period to assess improvements in their skin condition and any potential side effects. The goal is to determine if Lebrikizumab can significantly improve the symptoms of eczema compared to the placebo.

In addition to Lebrikizumab, the study will also consider the effects of other treatments such as glucocorticoids, which are oral medications that help reduce inflammation, and various types of topical corticosteroids, which vary in potency from weak to very potent. The study will help understand the best treatment options for managing moderate-to-severe eczema in young patients.

]]>